Rob Volansky on Muck Rack

Rob Volansky

Verified
Philadelphia
As seen in: Healio, Flipboard, EIN News, Healio Cardiac/Vascular Intervention, Healio Cardiology, Healio Gastroenterology, Healio Neurology, Healio Primary Care, HemOnc Today, Nephrology News & Issues, Primary Care Optometry News and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rob

Contact Rob, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA updates Tremfya label to include joint damage inhibition in psoriatic arthritis

|
By Rob Volansky 
| Healio
FDA updates Tremfya label to include joint damage inhibition in psoriatic arthritis Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Open in Who Shared Issue with article?

Aspirin at giant cell arteritis diagnosis reduces heart risk, increases hemorrhage odds

|
By Rob Volansky 
| Healio
Key takeaways: Low-dose aspirin initiated at giant cell arteritis diagnosis reduced major cardiovascular event risk at 1 year. However, low-dose aspirin also increased the risk for major hemorrhage. Low-dose aspirin initiated giant cell arteritis diagnosis reduced the risk for major adverse cardiac events at 1 and 3 years, but increased risk for major hemorrhage at 1 year, according to data published in JAMA Network Open.
Open in Who Shared Issue with article?

Vunakizumab bests placebo in radiographic axial spondyloarthritis symptom improvement

|
By Rob Volansky 
| Healio
Key takeaways: Vunakizumab 120 mg bested placebo in ASAS20 response at 16 weeks in active axial SpA. Safety data showed no difference in adverse events between vunakizumab and placebo. Vunakizumab, a novel interleukin 17a monoclonal antibody, is superior to placebo in radiographic axial spondyloarthritis symptom improvement, according to data published in JAMA Network Open.
Open in Who Shared Issue with article?
See all 1,264 articles

Actions

Share this page

Get in touch with Rob

Contact Rob, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified